Classification of Medicines Pursuant to section 106 (1) of the Medicines Act 1981, I, G. R. Boyd, Chief Advisor, Regulation and Safety, hereby declare the following: 1. The medicines listed in Schedule 1 to this notice are classified as prescription medicines. 2. The medicines listed in Schedule 2 to this notice are classified as restricted medicines. 3. The medicines listed in Schedule 3 to this notice are classified as pharmacy-only medicines. Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources. Unless specific reference is made otherwise, every reference applies also to medicines that are (a) Preparations and admixtures containing any proportion of any substance listed in the notice; (b) Salts and esters of any substance listed in the notice; (c) Preparations or extracts of biological materials listed in the notice; (d) Salts or oxides of elements listed in the notice. Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise. Schedule 1 Prescription Medicines astemizole basiliximab cerivastatin daclizumab desonide fluvoxamine grepafloxacin ibandronic acid imiquimod meloxicam mibefradil montelukast orlistat topotecan valsartan vinorelbine zolmitriptan zolpidem Schedule 2 Restricted Medicines amorolfine; for external use in medicines containing more than 0.25% flurbiprofen; in throat lozenges containing 10 milligrams or less per lozenge Schedule 3 Pharmacy-only Medicines amorolfine; for external use in medicines containing 0.25% or less *ibuprofen; in liquid form for oral use in medicines which are sold in the manufacturer's original pack containing 200 millilitres or less in volume and in strengths of 100 milligrams or less per 5 millilitres levocabastine *Regulation 20 of the Medicines Regulations 1984 requires that all medicines sold without a practitioner's prescription must include a consumer information panel on the label. Further, all material changes to a medicine (including changes to labelling), must be notified to the Director-General of Health in accordance with section 24 of the Medicines Act 1981. Dated this 18th day of August 1998. G. R. BOYD, Chief Advisor, Regulation and Safety.